Pharmaceuticals Acquisitions in 2018

Novacap has completed the acquisition of PCI Synthesis, a U.S.-based small-molecule CDMO with R&D and manufacturing sites in Massachusetts. The deal gives Novacap a U.S. footprint and strengthens its global pharmaceutical synthesis and commercial manufacturing capabilities.

Charterhouse-backed Cooper-Vemedia has acquired a portfolio of 12 over-the-counter (OTC) pharmaceutical brands from Sanofi for €158 million. The brands—spanning dermatology, well-being, eye care and other categories—are predominantly sold in France and Italy and will be integrated into Cooper-Vemedia’s pan‑European OTC platform to strengthen its product offering and market position.

THI Investments, a single-family office, is making a EUR 60 million strategic growth investment in Apologistics, one of Germany's largest online pharmacies, to expand logistics capacity and strengthen its technology platform. Apologistics will expand its Leipzig site and build a second fully automated logistics centre to enable same-day delivery across Germany and pursue market consolidation.